Page 7 - Rgene Technologies News Today

View the winners of the 2021 BioBuzz Awards, a celebration of the exciting work being done by the BioHealth Capital Region community.

/PRNewswire/ -- The "Global Gene Delivery Technologies Market 2021-2028" report has been added to ResearchAndMarkets.coms offering. The global gene delivery...

Dr. Conant, one of the first HIV/AIDS treatment pioneers, strengthens AGT’s capacity to progress toward a functional cure...

- The genome engineering market is expected to expand at a CAGR of 10.9% CAGR during 2019-2027. This growth can be attributed to the growing funding toward genomic research and technological

/PRNewswire/ -- The global genome engineering market is projected to experience substantial expansion avenues in the forecast period of 2019 to 2027. This...

Nachricht vom 23.07.2021 | 07:01 Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin Lonza Group AG / Key word(s): Half Year Results 23-Jul-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7% 1 sales growth and 33.3% CORE EBITDA margin, de...

EQS-Adhoc: Lonza ... EQS-Adhoc: Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin vom 23.07.2021, 07:01 Uhr Bild: pixabay.com EQS Group-Ad-hoc: Lonza Group AG / Key word(s): Half Year Results Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin 23-Jul-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announc...

EQS-Adhoc: Lonza Group AG: Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin 23-Jul-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad Hoc Release Pursuant to Art. 53 Listing Rules In H1 2021, Lonza continued its strong performance with 14.7% 1 sal...

HIV Cure Program Releases Initial Clinical Trial Data July 15, 2021 23:51 ET | Source: American Gene Technologies American Gene Technologies Rockville, Maryland, UNITED STATES ROCKVILLE, Md., July 15, 2021 (GLOBE NEWSWIRE) -- American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data re...

Lonza Publishes Restated Financials for 2020 Search jobs Lonza Group AG / Key word(s): Annual Results/Half Year Results 29-Jun-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Lonza reports restated 2020 financials for sales, EBIT, EBITDA and CORE EBITDA Lonza now provides 2020 financials in the redesigned business structure to reflect divisional performance   Basel, Switzerland, 29 June 2021 ...